Dr. Nancy Tawil has a solid multidisciplinary background in human physiology (B.Sc. McGill), chemical engineering (M.Eng. École Polytechnique), and biomedical engineering (Ph.D. École Polytechnique).

Her research focuses on the development of innovative delivery systems which allow the sustained release of novel antimicrobials. These strategies are nested in the current need to resolve biofilms and multi-drug resistant infections. Her expertise and interests include drug delivery, physico-chemical characterization, polymer chemistry, periprosthetic joint infections, novel combination devices, antibiotic resistance, and nanotechnology.

In her current role as the Chief Scientific Officer at Phagelux Inc., she is responsible for the management of a global, multidisciplinary team.  She oversees laboratories and scientists in Canada and China. Her success as a leader in the industry of bacteriophage and lysin research has allowed for a multitude of global partnerships and collaborative efforts, as well as the translation of Phagelux’s technologies into human clinical trials.

Dr. Tawil continues to foster strong working relationships with professors in Canada and around the world, as well as governmental entities in Canada  and in the United Sates. In the past 3 years she has been an invited speaker at multiple international conferences, including the World Anti-Microbial Resistance Congress, and the US Presidential Advisory Council on Combating Antibiotic- Resistant Bacteria (PACCARB). As an Associate Professor, she would continue to foster these relationships and further reinforce École Polytechnique de Montréal’s standings as a leader in research and innovative development in the field of antimicrobials.